{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:08:58Z","timestamp":1779275338411,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11845-025-04260-4","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:54:20Z","timestamp":1768622060000},"page":"667-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence to Bacille Calmette-Guerin protocol in the management of non-muscle invasive bladder cancer at St James\u2019s Hospital"],"prefix":"10.1007","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-0917","authenticated-orcid":false,"given":"Jody SA","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E","family":"Lonergan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise C","family":"McLoughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"4260_CR1","doi-asserted-by":"publisher","first-page":"04109","DOI":"10.7189\/jogh.13.04109","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Rumgay H, Li M et al (2023) The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health 13:04109. https:\/\/doi.org\/10.7189\/jogh.13.04109","journal-title":"J Glob Health"},{"issue":"1","key":"4260_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12672-025-01828-5","volume":"16","author":"P Saarinen","year":"2025","unstructured":"Saarinen P, Jokelainen O, Ruotsalainen L et al (2025) The usage of the Paris classification system in urine cytology in the diagnosis of non-muscle-invasive bladder cancer: a retrospective single-center study. Discov Oncol 16(1):95. https:\/\/doi.org\/10.1007\/s12672-025-01828-5","journal-title":"Discov Oncol"},{"issue":"5","key":"4260_CR3","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964\u201370. https:\/\/doi.org\/10.1016\/S0022-5347(05)64273-5","journal-title":"J Urol"},{"issue":"6","key":"4260_CR4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6):1216\u20131223. https:\/\/doi.org\/10.1016\/j.urology.2005.12.014","journal-title":"Urology"},{"issue":"4","key":"4260_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"issue":"1","key":"4260_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R et al (2014) Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65(1):69\u201376. https:\/\/doi.org\/10.1016\/j.eururo.2013.07.021","journal-title":"Eur Urol"},{"issue":"3","key":"4260_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/BLC-179018","volume":"3","author":"EM Messing","year":"2017","unstructured":"Messing EM (2017) The BCG shortage. Bladder Cancer 3(3):227\u2013228. https:\/\/doi.org\/10.3233\/BLC-179018","journal-title":"Bladder Cancer"},{"issue":"14","key":"4260_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/CEOR.S341896","volume":"10","author":"MG Musat","year":"2022","unstructured":"Musat MG, Kwon CS, Masters E et al (2022) Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR). Clinicoecon Outcomes Res 10(14):35\u201348. https:\/\/doi.org\/10.2147\/CEOR.S341896","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"4260_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63(3):462\u2013472. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039","journal-title":"Eur Urol"},{"issue":"5","key":"4260_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"CV Nikas","year":"2020","unstructured":"Nikas CV, Smith AB (2020) Goldilocks and the BCG: Bacillus Calmette-Gu\u00e9rin dose reduction in the age of shortage. Eur Urol 78(5):699\u2013700. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.066","journal-title":"Eur Urol"},{"issue":"6","key":"4260_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MOU.0000000000001218","volume":"34","author":"Kurnot","year":"2024","unstructured":"Kurnot, Jeremy AA, Kaye, Deborah RABCD (2024) Reducing financial toxicity in bladder cancer care. Curr Opinion Urol 34(6):484\u2013488. https:\/\/doi.org\/10.1097\/MOU.0000000000001218","journal-title":"Curr Opinion Urol"},{"issue":"9","key":"4260_CR12","doi-asserted-by":"publisher","first-page":"391.e1","DOI":"10.1016\/j.urolonc.2023.04.005","volume":"41","author":"L Bukavina","year":"2023","unstructured":"Bukavina L, Bell S, Packiam VT et al (2023) Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-guerin (BCG) in the treatment of non-muscle invasive bladder cancer: a preliminary cost-effectiveness analysis. Urol Oncol 41(9):391.e1-391.e4. https:\/\/doi.org\/10.1016\/j.urolonc.2023.04.005","journal-title":"Urol Oncol"},{"issue":"4","key":"4260_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"A B\u00f6hle","year":"2004","unstructured":"B\u00f6hle A, Bock PR (2004) Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682\u2013686. https:\/\/doi.org\/10.1016\/j.urology.2003.11.049","journal-title":"Urology"},{"issue":"12","key":"4260_CR14","doi-asserted-by":"publisher","first-page":"e26323","DOI":"10.2196\/26323","volume":"23","author":"A Uslu","year":"2021","unstructured":"Uslu A, Stausberg J (2021) Value of the electronic medical record for hospital care: update from the literature. J Med Internet Res 23(12):e26323. https:\/\/doi.org\/10.2196\/26323","journal-title":"J Med Internet Res"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-04260-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:40:56Z","timestamp":1779273656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-04260-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-04260-4","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}